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Abstract
Background: For accurate nodal staging, all blue and radioactive lymph nodes should be sampled
during the sentinel lymph node biopsy for breast cancer. We report a case of anomalous drainage
in which one of the sentinel lymph nodes was unexpectedly found in the level III axillary space.
Case presentation: A 40-year-old female underwent mastectomy for extensive high-grade ductal
carcinoma in-situ (DCIS) with micro-invasion. The index lesion was located in the right upper inner
quadrant. Lymphoscintigraphy was performed on the morning of surgery. Two sentinel lymph
nodes were identified. At operation, 5 mls of isosulfan blue dye was injected at the same site of the
radio-colloid injection. The first sentinel lymph node was found at level I and was blue and
radioactive. The second sentinel node was detected in an unexpected anomalous location at level
III, medial to the pectoralis minor. Both sentinel nodes were negative.
Conclusion: Sentinel node staging can lead to unexpected patterns of lymphatic drainage. For
accurate staging, it is important to survey all potential sites of nodal metastasis either with
preoperative lymphoscintigraphy and/or rigorous examination of regional nodal basins with the
intra-operative gamma probe.
Background
Sentinel lymph node biopsy has become the standard of
care in staging the clinically negative axilla in patients
with breast cancer. Although its role in patients with duc-
tal carcinoma-in-situ is controversial, most would agree
that it is indicated in the patient being described, as she
had both micro-invasion as well as multifocal disease
requiring mastectomy (the latter indication being justified
in case unexpected invasive cancer is discovered at a site
different than that of the index lesion)[1,2]. For accurate
nodal staging, removal of all sentinel nodes is important
not only to guide postoperative therapy but also for
regional control of disease should these nodes contain
metastases. Prior to sentinel node biopsy, the standard of
care for nodal staging has been level I and II axillary node
dissection. The advent of this new technique has now
afforded the ability to ultra-stage a limited number of
nodes with intense multi-section analysis as well as
immunohistochemistry [3]. Furthermore, detection of
nodes with radioactivity is now able to identify draining
nodes in unexpected locations that would otherwise have
been missed by standard axillary node dissection.
Case presentation
A 40-year-old female presented with suspicious increasing
micro-calcifications in the right breast. A stereotactic
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biopsy of the most worrisome area in the right upper
inner quadrant demonstrated ductal carcinoma in-situ
with microinvasion. Because of the diffuse extent of the
malignant appearing calcifications, a mastectomy was rec-
ommended. On the morning of surgery, a 0.4 mCi dose of
filtered Tc-99 m sulfur colloid was injected subdermally at
the biopsy site. Two sentinel lymph nodes were identified,
one at level I and a second, that was very medial and inter-
preted as a possible internal mammary node (Figure 1). In
the operating room, 5 ml of isosulfan blue dye was
injected subdermally near the biopsy site, and the proce-
dure was started after 5 minutes of skin massage. The first
sentinel lymph node was found at level I and was blue
and radioactive. Continued dissection at level I did not
demonstrate any other radioactive or blue-stained lymph
nodes. However, using the lymphoscintigraphy as our
guide, we performed a more thorough search for the sec-
ond sentinel node in the internal mammary chain and
under the most medial part of the clavicle. Radioactivity
was detected in the latter location, suggesting a level III
sentinel lymph node, i.e., medial to the pectoralis minor.
Since it was not easily accessible through the small axillary
incision, we proceeded with the mastectomy then dis-
sected the remaining sentinel node through a trans-pecto-
ral approach. The medial aspect of the pectoralis major was
divided in the direction of its fibers, thus allowing access
to the level III space medial to the pectoralis minor, where
a blue and radioactive lymph node was identified and
Lymphoscintigraphy demonstrating the location of the primary tumor in the upper inner quadrant of the right breast (large  central area of radioactivity) as well as the two sentinel lymph nodes Figure 1
Lymphoscintigraphy demonstrating the location of the primary tumor in the upper inner quadrant of the right breast (large 
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removed (Figure 2). The patient had an unremarkable
postoperative course and was discharged on the first post-
operative day. Final pathology demonstrated multifocal
micro-invasive comedo-DCIS in the upper inner, upper
outer, and retro-areolar regions of the breast. Both senti-
nel lymph nodes were negative for metastatic disease
based on routine histology as well as immunohistochem-
istry for cytokeratin.
A blue-stained and radioactive level III sentinel lymph node is demonstrated at the end of the Allis clamp Figure 2
A blue-stained and radioactive level III sentinel lymph node is demonstrated at the end of the Allis clamp. This was dissected via 
a transpectoral approach.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
World Journal of Surgical Oncology 2006, 4:31 http://www.wjso.com/content/4/1/31
Page 4 of 4
(page number not for citation purposes)
Discussion
Studies of lymphatic drainage patterns from the breast
have demonstrated that up to 19% of cases will demon-
strate sentinel node activity outside the expected level I
and II basins of the axilla (i.e., lateral to the medial border
of the Pectoralis minor) [4]. Although the incidence of iso-
lated metastatic disease to level III (medial to the Pectoralis
minor) is < 2%, the likelihood of tumor involvement at
this level is significantly increased if there are concomitant
positive nodes in levels I and II [5,6]. Therefore, it is man-
datory that all identified sentinel nodes be removed for
complete staging as well as regional control of disease. In
this case, sentinel node detection allowed more accurate
complete staging since the level III node would not have
been included in a standard level I and II axillary node dis-
section. Because the patient was undergoing mastectomy,
access to the level III node was available through the
transpectoral approach described. Bevilacqua et al., have
proposed a management algorithm for patients in whom
the approach to the anomalous sentinel node may be
technically more difficult than in our patient, i.e., those
undergoing local excision rather than mastectomy, or
those with an internal mammary sentinel node [7]. The
first situation is that of simultaneous sentinel nodes in the
expected axillary location as well as in an anomalous loca-
tion. In this instance, the former are dissected and sent for
frozen section analysis. If the axillary sentinel nodes are
positive for metastatic disease, then a standard axillary
dissection is performed, and the anomalous node is not
removed if it is in the internal mammary location (or can
be included in the axillary lymphadenectomy if it is at
level III). If, however, the axillary sentinel node is negative
for metastatic disease or if no axillary sentinel node is
identified, then efforts must be made to retrieve the
anomalous sentinel node so that the patient may be accu-
rately staged.
Conclusion
Our case illustrates the degree to which sentinel lymph
node biopsy has improved the ability to stage the patient
with breast cancer. Not only can intense   histological and
immunohistochemical analysis be limited to a small
number of nodes that have the highest probability of con-
taining  metastases, but it also allows identification of first
echelon draining   nodes that would normally be missed
with a standard axillary node   dissection.
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